|1.||Paquette, Melanie A: 3 articles (06/2013 - 01/2008)|
|2.||Berger, S Paul: 2 articles (06/2013 - 07/2009)|
|3.||Meshul, Charles K: 2 articles (07/2009 - 01/2008)|
|4.||Johnson, Steven W: 2 articles (07/2009 - 01/2008)|
|5.||Brudney, Elizabeth G: 2 articles (07/2009 - 01/2008)|
|6.||Bishop, Christopher: 1 article (06/2013)|
|7.||Surrena, Margaret A: 1 article (06/2013)|
|8.||Bhide, Nirmal: 1 article (06/2013)|
|9.||Lindenbach, David: 1 article (06/2013)|
|10.||Goldenberg, Adam A: 1 article (06/2013)|
|1.||Schizophrenia (Dementia Praecox)
07/01/2009 - "BMY-14802 is a promising candidate for clinical trials due to its extremely low affinity for the D2 receptor and lack of extrapyramidal effects during prior clinical trials for schizophrenia."
02/01/1994 - "We report here the results of an uncontrolled, multicenter safety and efficacy study of patients with acute exacerbations of schizophrenia treated with BMY 14802. "
02/01/1994 - "BMY 14802, a sigma receptor ligand for the treatment of schizophrenia."
01/01/1993 - "If clinically efficacious, BMY 14802 may treat the symptoms of schizophrenia by a mechanism novel for antipsychotic drugs: regionally selective, indirect modulation of dopaminergic systems by specific interaction at sigma sites."
07/01/1999 - "The report on clinical trial targeting schizophrenia shows results on rimcazole, remoxipride, BMY 14802, panamesine (EMD 57445) and SL 82.0715. "
07/01/2009 - "The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism."
06/01/2013 - "Results confirmed the dose-dependent (20 > 10 > 5 mg/kg) anti-dyskinetic effects of BMY-14802 against L-DOPA with preservation of anti-parkinsonian efficacy at 10 mg/kg. BMY-14802 at 10 and 20 mg/kg also reduced dyskinesia induced by both D1 and D2 receptor agonists. "
06/01/2013 - "The purported sigma-1 antagonist, BMY-14802 has been previously demonstrated to reduce L-DOPA induced dyskinesia in a 5-HT1A receptor dependent manner. "
06/01/2013 - "The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat."
01/08/2008 - "Dyskinesias, however, were suppressed by the NMDA and sigma (sigma)-1 receptor ligand dextromethorphan and by the sigma-1 antagonist BMY-14802. "
01/01/1992 - "BMY-14802 (10, 30 and 50 mg/kg) did not produce any stereotyped behavior, ataxia or seizures. "
03/01/1991 - "Caramiphen and ifenprodil (ED50 = 52 and 61 mg/kg, respectively) also blocked maximal electroshock-induced seizures, whereas BMY 14802 and haloperidol were ineffective. "
03/01/1991 - "BMY 14802, haloperidol and ifenprodil only partially antagonized NMDA-induced seizures, but did enhance the anticonvulsant potency of the noncompetitive NMDA antagonist, MK-801. "
07/01/1991 - "administration of BMY 14802 alone (25.0 mg/kg) decreased body temperature and enhanced the DTG-induced hypothermia, whereas the administration of rimcazole (25.0 mg/kg) neither altered body temperature nor affected the hypothermia produced by DTG. "
10/29/1991 - "In common with 5-HT1A receptor agonists or partial agonists, BMY 14802 induced (a) a dose-dependent hypothermia in mice; (b) aspects of the 5-HT behavioural syndrome in rats, (c) antagonised mescaline-induced head twitches in mice and (d) generalised to the 8-hydroxy-2-(di-n-propylamino)tetralin discriminative stimulus over the dose range of 3-15 mg/kg. BMY 14802 had appreciable affinity for the 5-HT1A receptor (pIC50 = 6.7 compared to 7.3 for sigma binding) and antagonised forskolin-stimulated adenylate cyclase activity with a pEC50 of 6.2, consistent with an agonist action at this receptor. "
|2.||5-HT1A Serotonin Receptor
|3.||sigma Receptors (sigma Receptor)
|5.||Antipsychotic Agents (Antipsychotics)
|6.||Levodopa (L Dopa)
|8.||Dopamine Agonists (Dopamine Agonist)